At Tegmine we target glycoproteins, which are a hallmark of numerous solid cancers and drive aggressive disease. We’ve engineered a system to generate revolutionary new antibody-based therapies for cancer which dramatically increase efficacy while reducing toxic side effects. Our proprietary TegMiner™ platform enables the discovery of unique cancer epitopes and allows us to develop these life-changing new antibodies for patients with unmet needs.
Company Details
- Employees
- 8
- Address
- South San Francisco, California 94080, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tegminetx.com
- HQ
- South San Francisco, California
Tegmine Therapeutics, Inc. Questions
Tegmine Therapeutics, Inc.'s website is tegminetx.com
Tegmine Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/tegmine-therapeutics
Tegmine Therapeutics, Inc. has
8 employees.
View email and phone details for 8
employees at Tegmine Therapeutics, Inc..
Tegmine Therapeutics, Inc.'s industry is
Biotechnology Research
Tegmine Therapeutics, Inc.'s top competitors are
Tizona Therapeutics, Inc.,
Tallac Therapeutics,
Avenzo Therapeutics,
Adicet Bio, Inc,
Unicycive Therapeutics,
Senti Biosciences,
Rondo Therapeutics,
Obi Pharma,
Sutro Biopharma, Inc.,
Summit Therapeutics, Inc..
Tegmine Therapeutics, Inc.'s categories are Biotechnology Research
